Fungal infections in children with haematologic malignancies and stem cell transplant recipients
- PMID: 32159231
- PMCID: PMC7231650
- DOI: 10.1111/bjh.16452
Fungal infections in children with haematologic malignancies and stem cell transplant recipients
Abstract
Children with haematologic malignancies and haematopoietic stem cell transplant recipients are at high risk for invasive fungal diseases (IFD). There has been an increased number of at-risk children over the past two decades due to improvements in cancer therapies resulting in improved survival of children with high-risk and refractory malignancies. The predominant organisms that cause IFD include Candida spp., Aspergillus spp. and the Mucorales molds. Clinical presentations of IFD vary based on host immune status and the causative organism. Though serum biomarkers such as the galactomannan assay and beta-D-glucan assay have been validated in adults, there are limited data regarding their diagnostic value in children. Thus, the gold standard for IFD diagnosis remains tissue biopsy with histopathological and microbiological evaluation. Treatment of IFD is multimodal and involves antifungal drugs, correction of immune dysfunction and surgical resection when feasible. Paediatric practice regarding IFD is largely extrapolated from data generated in adult patients; in this review, we evaluate both primary paediatric studies and guidelines intended for adult patients that are applied to paediatric patients. There remain significant knowledge gaps with respect to the prevention, diagnosis and treatment of IFD in immunocompromised children, and further research is needed to help guide management decisions.
Keywords: antifungal prophylaxis; hematologic malignancies; immunocompromised; invasive fungal disease; pediatric.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Figures


Similar articles
-
Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.J Antimicrob Chemother. 2012 Nov;67(11):2731-8. doi: 10.1093/jac/dks266. Epub 2012 Jul 31. J Antimicrob Chemother. 2012. PMID: 22850692
-
Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.J Antimicrob Chemother. 2013 Nov;68 Suppl 3:iii5-16. doi: 10.1093/jac/dkt389. J Antimicrob Chemother. 2013. PMID: 24155144
-
Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.Transpl Infect Dis. 2019 Jun;21(3):e13066. doi: 10.1111/tid.13066. Epub 2019 Mar 27. Transpl Infect Dis. 2019. PMID: 30859662
-
Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.Biol Blood Marrow Transplant. 2015 Jun;21(6):1117-26. doi: 10.1016/j.bbmt.2015.03.018. Epub 2015 Mar 31. Biol Blood Marrow Transplant. 2015. PMID: 25840339
-
Triggers for driving treatment of at-risk patients with invasive fungal disease.J Antimicrob Chemother. 2013 Nov;68 Suppl 3:iii17-iii24. doi: 10.1093/jac/dkt391. J Antimicrob Chemother. 2013. PMID: 24155142
Cited by
-
[Clinical features and prognosis of children with fungal bloodstream infection following chemotherapy for acute leukemia].Zhongguo Dang Dai Er Ke Za Zhi. 2024 Oct 15;26(10):1086-1092. doi: 10.7499/j.issn.1008-8830.2406021. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 39467679 Free PMC article. Chinese.
-
Antifungal combinations in paediatric invasive fungal infections: a protocol for systematic review and meta-analysis.BMJ Open. 2024 Oct 29;14(10):e085593. doi: 10.1136/bmjopen-2024-085593. BMJ Open. 2024. PMID: 39477280 Free PMC article.
-
Surgical treatment of invasive pulmonary fungal infections in immunocompromised pediatric patients: Aspergillus spp. and other emerging fungi.Pediatr Surg Int. 2024 Oct 5;40(1):263. doi: 10.1007/s00383-024-05851-5. Pediatr Surg Int. 2024. PMID: 39367968
-
Case Report: Sudden Fatal Hemorrhage in Ulcerative Fungal Laryngotracheitis-A Pediatric Case Report.Front Pediatr. 2022 Jan 11;9:764027. doi: 10.3389/fped.2021.764027. eCollection 2021. Front Pediatr. 2022. PMID: 35087772 Free PMC article.
-
Diagnostic and Therapeutic Challenge Caused by Candida albicans and Aspergillus spp. Infections in a Pediatric Patient as a Complication of Acute Lymphoblastic Leukemia Treatment: A Case Report and Literature Review.Pathogens. 2024 Sep 7;13(9):772. doi: 10.3390/pathogens13090772. Pathogens. 2024. PMID: 39338963 Free PMC article. Review.
References
-
- Afzal S, Ethier MC, Dupuis LL, Tang L, Punnett AS, Richardson SE, Allen U, Abla O & Sung L (2009) Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J, 28, 1064–1068. - PubMed
-
- Arendrup MC, Cuenca-Estrella M, Lass-Florl C & Hope WW (2013) Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat, 16, 81–95. - PubMed
-
- Azik FM, Tezer H, Ozkaya-Parlakay A, Aksu T, Bayram C, Fettah A, Tavil B & Tunc B (2015) Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants. J Pediatr Hematol Oncol, 37, e19–22. - PubMed
-
- Barg AA, Malkiel S, Bartuv M, Greenberg G, Toren A & Keller N (2018) Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer, 65, e27281. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous